We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Potential Synergy of Radiation Therapy With Vismodegib for Basal Cell Carcinoma

John M. Strasswimmer, MD, PhD1,2
[+] Author Affiliations
1Departments of Surgery, Internal Medicine, and Biochemistry, Florida Atlantic University, Boca Raton, Florida
2Lynn Cancer Institute, Moffitt Oncology Network, Boca Raton Regional Hospital, Boca Raton, Florida
JAMA Dermatol. 2015;151(9):925-926. doi:10.1001/jamadermatol.2015.0977.
Text Size: A A A
Published online


Basal cell carcinoma (BCC), when untreated, causes significant morbidity and mortality. Challenging tumors are regularly reviewed in multimodality tumor boards and are classified not by metastatic risk (inherently very low) but by histologic type and other tumor characteristics. Tumors are thus triaged appropriately to destruction, excision, topical therapy, Mohs surgery, or ionizing radiation therapies. The cure rate for BCC with monotherapy has largely exceeded that for other human cancers, prompting some to lose sight of the tremendous challenge it still creates.1 The increasing number of these cancers and the increasing longevity of patients leaves us with more complex BCC tumors to manage. We now have a type of chemotherapy available for BCC, and with the 2 cases reported in this issue of JAMA Dermatology, Pollom et al2 demonstrate the possibility of true combination therapy.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

1 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles

Care at the Close of Life: Evidence and Experience
Radiation Therapy

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Evidence Summary and Review 3